Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 West 4th Ave, Vancouver, Canada

snowPOW Nov. 18 at 5:11 AM

$ABCL spicy

0 · Reply

Ed_Ng Nov. 18 at 3:01 AM

$ABCL still very very accurate!

1 · Reply

Ed_Ng Nov. 18 at 2:04 AM

$ABCL what if it goes lower? Then you will say it goes up. Just a BS

1 · Reply

stayquill Nov. 18 at 1:14 AM

What a call today in this red market by @CoralSharkie been dropping better calls than 99% on this app🔥 Worth following it doesn’t cost anything but a click!! Show him some love💚 He made my day green fr with this call. Thank you🙏 $ABCL $FBIO $SNDX $TGTX

0 · Reply

estatebuyersmia Nov. 18 at 12:35 AM

$ABCL My guess is the stock is basing here for its next move up... ED NG BETTER COVER YOUR SHORT POSITION...

0 · Reply

estatebuyersmia Nov. 18 at 12:27 AM

$ABCL ED NG ISNT TOO BRIGHT... YES SOMEONE SOLD BUT '' SOMEONE BOUGHT"... IF THERE WERE NO INTEREST THE STOCK WOULD DROP TO 2... HOW DUMB CAN YOU BE?

0 · Reply

HedgeAlerts Nov. 18 at 12:03 AM

Hedge Alert Live - Protect Your Portfolio Contract: $ABCL $3.00 Put · DEC 19, 2025 Exp Entry Price: $0.15 - $0.20 Exit Price Target: $0.36 Profit Margin: +139% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Ed_Ng Nov. 17 at 11:10 PM

$ABCL it's over. Someone just sold 356.28k shares at 3.6$. Must be insider or institution.

1 · Reply

estatebuyersmia Nov. 17 at 9:13 PM

$ABCL The market today made a double bottom from Oct 10th lows and $ABCL held beautifully which tells me it will rally from here.

0 · Reply

PattyBergeron Nov. 17 at 8:55 PM

$ABCL this stock may pick up in 3-10 years. Until then it will go up and down a lot. Im just buying and holding. If i could time the swings i would. I broken clock is right twice a day though. 😜

0 · Reply

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 7, 2025, 7:16 PM EST - 10 days ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 11 days ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 5 weeks ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 6, 2025, 7:35 AM EDT - 6 weeks ago

AbCellera Biologics: Entering Growth Phase After A Pause

Sep 29, 2025, 4:05 PM EDT - 7 weeks ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 2 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 2 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 7:48 PM EDT - 3 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 6 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 6 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 6 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 6 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 10:33 PM EDT - 6 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 6 months ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 7 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 8 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 11:26 PM EST - 9 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 10 months ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 11 months ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 23, 2024, 4:39 PM EST - 11 months ago

AbCellera Biologics: Still A Concept Stock

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 8, 2024, 12:05 PM EDT - 1 year ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 19, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 1 year ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

snowPOW Nov. 18 at 5:11 AM

$ABCL spicy

0 · Reply

Ed_Ng Nov. 18 at 3:01 AM

$ABCL still very very accurate!

1 · Reply

Ed_Ng Nov. 18 at 2:04 AM

$ABCL what if it goes lower? Then you will say it goes up. Just a BS

1 · Reply

stayquill Nov. 18 at 1:14 AM

0 · Reply

estatebuyersmia Nov. 18 at 12:35 AM

$ABCL My guess is the stock is basing here for its next move up... ED NG BETTER COVER YOUR SHORT POSITION...

0 · Reply

estatebuyersmia Nov. 18 at 12:27 AM

$ABCL ED NG ISNT TOO BRIGHT... YES SOMEONE SOLD BUT '' SOMEONE BOUGHT"... IF THERE WERE NO INTEREST THE STOCK WOULD DROP TO 2... HOW DUMB CAN YOU BE?

0 · Reply

HedgeAlerts Nov. 18 at 12:03 AM

0 · Reply

Ed_Ng Nov. 17 at 11:10 PM

$ABCL it's over. Someone just sold 356.28k shares at 3.6$. Must be insider or institution.

1 · Reply

estatebuyersmia Nov. 17 at 9:13 PM

$ABCL The market today made a double bottom from Oct 10th lows and $ABCL held beautifully which tells me it will rally from here.

0 · Reply

PattyBergeron Nov. 17 at 8:55 PM

$ABCL this stock may pick up in 3-10 years. Until then it will go up and down a lot. Im just buying and holding. If i could time the swings i would. I broken clock is right twice a day though. 😜

0 · Reply

NemesisTrade Nov. 17 at 8:54 PM

Top after hours squeeze watch is CLIK - Parabolic potential 💎 Only micro 300k shares available to public. Starting to see some big buyers on CLIK now, Bulls moving to CLIK $ABCL $FBIO $SNDX $TGTX @@

1 · Reply

JoeTheMiner Nov. 17 at 8:37 PM

$ABCL Might be interested in $GUTS ??

0 · Reply

Ed_Ng Nov. 17 at 7:37 PM

$ABCL going as planned.

0 · Reply

Plutten1973 Nov. 17 at 7:32 PM

$ABCL i hope and think we turn up.from here ,if not hmmmm?

0 · Reply

JBurckhardt Nov. 17 at 7:02 PM

$PRLD "Per Prelude's 10-Q, the amended/expanded $ABCL deal (Q3-Oct 2025) gave AbCellera a non-exclusive license to use Prelude's degrader payloads and worldwide control of the newly licensed DAC programs at AbCellera's cost. Prelude is eligible for customary downstream milestones and single-digit royalties on those additional licensed DACs, and the original 2023 joint collaboration (up to five programs) remains in effect."...(beyond the $6 million cash Prelude receives right now)

0 · Reply

HedgeAlerts Nov. 17 at 6:47 PM

Hedge Alert Live - Protect Your Portfolio Contract: $ABCL $3.00 Put · DEC 19, 2025 Exp Entry Price: $0.17 - $0.20 Exit Price Target: $0.28 Profit Margin: +65% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Ed_Ng Nov. 17 at 5:47 PM

$ABCL blood today and this week. 2$ coming fast!

0 · Reply

Stocktradesmoon Nov. 17 at 4:29 PM

$ABCL $ABCL is setting up with a very attractive chart structure right now. Wave 3 price target sits at $9.79. #ABCL #Stocks

0 · Reply

Ed_Ng Nov. 17 at 4:23 PM

$ABCL $RLYB penny boy does penny stock. lol better to go to MGM and play black jack.

0 · Reply

estatebuyersmia Nov. 17 at 4:09 PM

$ABCL TO ED NG: WATCH $RLYB IT MAY BE A PENNY STOCK NOW BUT IT ONCE TRADED AT 20 DOLLARS AND ITS COMING BACK, NOT ME HOPING, ME KNOWING... I DO EXTENSIVE RESERACH, LOOK AT CASH POSITIONS, MANAGEMENT, PIPELINES ETC.. JUST WATCH.. MAYBE YOU CAN LEARN....

0 · Reply

Ed_Ng Nov. 17 at 4:06 PM

$ABCL that's a different way to say bagholders are stupid ;-). Lot of short people here, maybe they blocked you.

0 · Reply

Ed_Ng Nov. 17 at 4:04 PM

$ABCL you don't ever do DCA? Or maybe you always all on penny stocks, so you don't even know what DCA strategy means? Okay, that explains

0 · Reply

Market Cap	1.10B
Revenue (ttm)	28.83M
Net Income (ttm)	-162.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-564.90%
Debt to Equity Ratio	0.00

Volume	4,611,700
Avg Vol	5,437,100
Day's Range	N/A - N/A
Shares Out	299.34M
Stochastic %K	12%
Beta	0.70
Analysts	Strong Sell
Price Target	$9.14